MA-ANTERRA-CAPITAL
29.6.2021 14:02:13 CEST | Business Wire | Press release
Anterra Capital (“Anterra”), the international food and agriculture specialist venture capital firm, today announced the initial closing of its second food and agriculture technology fund, Anterra F&A Ventures II, raising $175 million, exceeding the targeted size of the fund. Due to the positive market reception for the fund’s mission and strategy, Anterra is tracking towards an upsized second fund, and anticipates a final closing in the third quarter, 2021.
Anterra’s unique investment approach has attracted commitments from a prestigious and aligned group of long-term oriented global investors, with continued support from Eight Roads Ventures, backed by Fidelity, and Rabo Investments, the captive investment arm of the largest global food and agricultural bank out of the Netherlands - Rabobank. New investors include Novo Holdings, a leading global life sciences investor based out of Denmark; Tattarang, one of Australia’s largest private investment groups and the holding company of the Forrest family’s private business interests; as well as other well-respected family offices, sovereign wealth funds, and state-owned investors that provide a global presence, spanning across multiple continents.
Anterra’s mission is to invest in and partner with entrepreneurs transforming our vital food economy through biotech and digital innovation across crop science, animal health, and human nutrition. As a research driven, value-focused specialist investor Anterra uniquely combines a traditional venture investment approach and “venture creation,” building and scaling transformative businesses with its deep industry knowledge and vast global network as a pioneer in the space. While investor interest is growing in the Food & Ag industry, early-stage investment in this essential segment significantly trails that of other key industries, for comparison, less than half of that in Pharma & Biotech (~$40 billion) and about a fifth of venture investment in Software (~$100 billion).
“The food economy is in critical condition, and new digital and biotech solutions are desperately needed in order to support better outcomes for farmers, consumers and the environment,” said Adam Anders, Managing Partner of Anterra Capital. “With the first close, we continue our mission to sustainably transform our food economy, building on our leadership position as an early-stage investor in markets such as plant and animal health, while actively expanding our investment activity across the food and agriculture value chain.”
Daniel Auerbach, Senior Managing Partner and Global Head of Eight Roads Ventures, one of Anterra’s original lead investors, added: “Within Food & Ag, Anterra sits at the intersection of life sciences and digital technology and our expanded investment reflects our confidence in Anterra’s mission, leadership and performance for us over the past eight years.”
“We are excited to partner with Anterra and support the fund’s transformational mission, which is aligned with our investment activity across the biotech space overall, and emphasizes our commitment to investing in innovation within Food & Agriculture,” said Kartik Dharmadhikari, a Partner of Novo Growth within Novo Holdings.
About Anterra
With offices in Amsterdam and Boston, Anterra Capital is an international specialist venture capital investor dedicated to financing the growth of technology-driven companies with incredible potential in food, agriculture, and animal health. Supported by multinational institutional investors, Anterra provides patient strategic capital to entrepreneurs and innovative companies sustainably transforming our global food system. Further information: www.anterracapital.com
About Eight Roads Ventures
Eight Roads Ventures is a global investment firm backed by Fidelity. Eight Roads Ventures manages $7bn of assets across its offices in China, Hong Kong, India, Japan, UK and the US. Our 50-year history of investing includes partnerships with over 300 companies such as Alibaba, AppsFlyer, BlackDuck, Chewy, Devoted Health, Flywire, Icertis, iPipeline, Kensho, Letgo, Made.com, Neo4j, Nuance, Paidy, Ping Identity, Pony.ai, PharmEasy, Shadowfax, Toast, Wallapop, WuXi PharmaTech, and Xoom. Further information: https://eightroads.com
About Novo Holdings A/S
Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information: http://www.novoholdings.dk
About Rabo Investments
Rabo Investments is Rabobank’s PE investment franchise. It has invested over €1.5 billion worldwide within the cutting-edge Food & Agri, Sustainability, and Healthcare sectors in the Netherlands and within the Food & Agri sector worldwide. The investments range from growth capital for innovative start-ups and scale-ups to investments in established companies and funds. Further information: https://raboinvestments.com
About Tattarang
Tattarang is one of Australia’s largest private investment groups and is owned by the Forrest family. Its diverse investment portfolio spans across agri-food, energy, resources, property and lifestyle. The group is made up of six business divisions including Harvest Road which is one of Australia’s largest and most diverse agricultural businesses with an expanding portfolio of high-quality foods. Further information: www.tattarang.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005357/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agendia to Showcase New Research on AI-Driven Digital Pathology at ESMO 20266.10.2026 14:00:00 CEST | Press release
Podium presentation by Co-Founder and Chief Research Officer Laura van ’t Veer introduces an AI-driven approach to MammaPrintTwo additional poster presentations from the FLEX Study Agendia, Inc., a leader in precision oncology for breast cancer, announced today that it will present new research during a podium presentation on the development of an artificial intelligence (AI)-driven digital pathology approach for MammaPrintⓇ at the European Society for Medical Oncology (ESMO) Congress 2026, which takes place October 23 to 27, 2026, in Madrid. The company will also present two additional posters at ESMO. AI-driven digital pathology approaches are rapidly developing to expand access to genomic testing globally. Agendia’s first presentation, submitted as a late-breaking abstract, focuses on the development and validation of an AI-driven MammaPrint approach based on the analysis of routine whole slide images of breast cancer tissue. The following are details of the late-breaking abstract t
ExaGrid Named Finalist for the MSP Channel Insights Awards 20266.10.2026 14:00:00 CEST | Press release
ExaGrid Nominated in 7 Categories for Industry Awards ExaGrid, the world’s largest independent backup storage vendor providing Tiered Backup Storage for the fastest backups and restores, largest scale-out system with deduplication, and the most comprehensive security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it has been nominated in seven categories for the annual MSP Channel Insights Awards. The MSP Channel Insights Awards celebrate innovation, expertise and success across the IT channel—recognizing the Managed Service Providers (MSPs), vendors, distributors, resellers and technology leaders driving customer outcomes and business growth. Voting to determine the winner in each category is underway now and closes on October 30, 2026. Winners of the MSP Channel Insights Awards will be announced on November 26, 2026, at an awards ceremony in London. The award categories that ExaGrid has been nominated for include: Vendor of the Year Vendor Channel Pr
IFF Identifies the Life-Stage Insights Shaping Dairy’s Future6.10.2026 13:00:00 CEST | Press release
IFF (NYSE: IFF)—a global leader in flavors, fragrances and health and biosciences, published its latest resource, Dear Dairy: The Life Stages Guide. This strategic guide reveals how manufacturers can unlock new opportunities by aligning dairy innovation with consumers' evolving needs throughout life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005026164/en/ “Dairy is one of the few categories that evolves alongside consumers throughout their lives,” said Rogerio de Almeida Prado, vice president of Global Dairy & BBC (Bakery, Bars and Confectionery) for IFF Taste. “Over time, expectations change. What builds trust in childhood may need to support identity, convenience or vitality later in life. The next wave of dairy innovation will be defined not by a single trend, ingredient or claim, but by an understanding of what consumers need at different times of their lives — and why.” Drawing on insights from Panoptic™, IFF's
Invivoscribe® Advances Molecular Clonality Testing Portfolio with Comprehensive LymphoTrack® Flex Suite6.10.2026 12:15:00 CEST | Press release
New ultra-high sensitivity tests enable objective, automation-ready, high-throughput clonality and MRD workflow. Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the complete LymphoTrack Flex suite, an integrated next-generation sequencing (NGS) solution to identify and track immunoglobulin and T-cell receptor gene rearrangements. As NGS-based immune receptor MRD analysis moves from academic laboratories into routine use in oncology research centers, the demand for standardized, high-throughput workflows is accelerating. Laboratories are seeking both greater efficiency and ultra-high sensitivity. This requires increasing DNA inputs while ensuring higher testing throughput and analytical performance. Translational programs need testing that is both reproducible and scalable across sites. LymphoTrack Flex meets these demands, bringing seven molecular targets (IGHV leader, IGH FR1, IGH FR2, IGH FR3, IGK, TR
Degreed Agents Enable Every Leader to Upskill Their Organization with Ease6.10.2026 12:00:00 CEST | Press release
Degreed was born with the mission to help everyone get credit for all of their learning and skills. Today, the company announces the latest phase of that journey with the release of Degreed agents, a connected system of AI agents that lets leaders and L&D teams automate personalized learning and skill building. Leaders set the direction, agents do the work, and together they form the foundation of a hybrid operating system for their workforce. Businesses today run workforce transformations as a relay. The CEO sets a mandate to get everyone AI-fluent. A talent leader then defines the end state while managers try to spot gaps on their own teams. L&D pulls reports by hand and builds what they can. Each handoff adds a delay. Now, agents can orchestrate all of that in real time. Degreed agents notice details that matter, like a promotion, a skill gap, or an engagement dip, and act on them without requiring a manager to notice, an admin to flag it, or L&D to build it. At launch, agents build
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom